Item 1.01 Entry into a Material Definitive Agreement.
On
The Private Placement is expected to occur in two tranches. At the closing of
the first tranche (the "First Closing"), subject to satisfaction or waiver of
certain closing conditions, including obtaining voting agreements (the "Voting
Agreements") from stockholders of the Company representing at least 50.1% of the
outstanding shares of common stock, Innoviva will purchase the maximum number of
Shares and Common Warrants issuable to Innoviva in compliance with any and all
applicable laws and without the requirement for the prior receipt of the
stockholders' approval under the listing requirements of the NYSE American,
which is anticipated to be approximately 1.0 million Shares and Common Warrants
to purchase approximately 1.0 million shares of common stock for an aggregate
purchase price of
At the first closing, Innoviva and the Company will enter into an investors
rights agreement (the "Investor Rights Agreement") which will provide that for
so long as Innoviva and its affiliates hold at least 12.5% of the outstanding
shares of common stock on a fully-diluted basis, Innoviva shall have the right
to designate two (2) directors to the board of directors of the Company (the
"Board"), and for so long as Innoviva and its affiliates hold at least 8% but
less than 12.5% of the outstanding shares of common stock on a fully-diluted
basis, Innoviva shall have the right to designate one (1) director to the Board,
subject to certain qualifications and conditions in the Investor Rights
Agreement. . The Company currently expects that Innoviva will appoint
Both the First Closing and the Second Closing are expected to close in the first quarter of 2020, subject to the satisfaction of certain closing conditions referenced above.
The Company expects to receive aggregate gross proceeds from the Private
Placement of approximately
The foregoing descriptions of the Securities Purchase Agreement and the transactions contemplated therein do not purport to be complete and are qualified in their entirety by reference to the full text of the Securities Purchase Agreement, the form of the Investor Rights Agreement, form of Voting Agreements, and the form of the Common Warrants, copies of which are filed as Exhibit 10.1, 10.2, 10.3 and 4.1 hereto, respectively, and incorporated by reference herein.
Item 3.02 Unregistered Sales of
The information contained above in Item 1.01 related to the Private Placement is
hereby incorporated by reference into this Item 3.02. Based in part upon the
representations of Innoviva in the Securities Purchase Agreement, the offering
and sale of the Shares and Common Warrants will be exempt from registration
under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities
Act"). The sales of the Shares and Common Warrants by the Company in the Private
Placement will not be registered under the Securities Act or any state
securities laws and the Shares and Common Warrants may not be offered or sold in
Item 8.01 Other Events.
On
In light of the transactions described elsewhere in this report, the Company no
longer intends to conduct an offering of common stock in reliance on the
registration statement on Form S-1 (File No. 333-235656), initially filed by the
Company with the
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 4.1 Form of Common Stock Warrant. 10.1 Securities Purchase Agreement, datedJanuary 27, 2020 , by and between the Company and Innoviva. 10.2 Form of Investor Rights Agreement, by and the Company and Innoviva. 10.3 Form of Voting Agreement, to be entered into by and between Innoviva and certain stockholders of the Company. 99.1 Press Release, datedJanuary 28, 2020 .
© Edgar Online, source